Tumour-associated peptides that bind to mhc molecules
CA 2736972 C · Owner: Immatics Biotechnologies Inc. · Inventors: Weinschenk, Toni; Rammensee, Hans Georg; Stevanovic, Stefan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a tumour-associated peptide containing an amino acid sequence which is selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 79 of the enclosed sequence protocol. Said peptide has the capacity to bond to a molecule of the human major histocompatibility complex (MHC) class I. The invention also relates to the use of the peptides for producing a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition which comprises at least one of the peptides.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 27, 2003 and granted August 5, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 27, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 27, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.